HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Second Warning, Second Unsafe Ingredient For Total Body Nutrition

This article was originally published in The Rose Sheet

Executive Summary

FDA's Sept. 28 warning letter to Total Body Nutrition also noted violative claims and labeling for its products marketed with the TBN brand and listed GMP problems. First methylsynephrine in 2016, now DMAA land firm on FDA enforcement radar.

You may also be interested in...

Poor Results For Supplementation To Curb Depression In First-Of-Kind Study

Supplementation with omega-3s, folic acid, vitamin D3, calcium and selenium did not reduce MDD onset in overweight subjects with history of depression, according to first RCT on effectiveness of two nutritional strategies and their combination in preventing depression among high-risk subjects.

FDA List Of Supplement Formulation Taboos Adds Ephedra-Like Ingredient

CFSAN warns seven companies about products marketed as supplements with labeling listing methylsynephrine as a dietary ingredient. The center also warned two of the firms their products contained other ingredients FDA previously began forcing off the market, DMAA and DMBA.

FDA Warnings Mark Tip Of Iceberg For Stimulant-Spiked Supplements – Study

Researchers' "particular concern" about the stimulant oxilofrine in sports nutrition supplements is that more than 1m youth athletes use the products. Based on labeling, adolescents could consume three times the highest pediatric dose allowed where oxilofrine is approved as a drug.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts